Update on Paragangliomas and Pheochromocytomas

Area of Science:

• Endocrinology
• Oncology
• Genetics

Background:

• Recent genomic studies have identified numerous genetic mutations implicated in pheochromocytoma and paraganglioma.
• These mutations predominantly impact the pseudo-hypoxic and kinase signaling pathways.
• Genetic alterations are linked to various hereditary syndromes, including neurofibromatosis, MEN (II and III), and von Hippel-Lindau syndrome.

Purpose of the Study:

• To summarize the genetic basis of pheochromocytoma and paraganglioma.
• To highlight newly associated lesions with these genetic mutations.
• To emphasize the role of pathological features and markers in predicting tumor malignancy.

Main Methods:

• Review of genomic studies identifying genetic mutations.
• Analysis of cellular pathways affected by these mutations.
• Examination of pathological features and immunochemical markers for predictive value.

Main Results:

• Identification of mutations in pseudo-hypoxic and kinase signaling pathways as key drivers.
• Association of genetic mutations with syndromes like Carney's triad and Carney-Stratakis syndrome.
• Recognition of gastrointestinal stromal tumor and renal cell carcinoma as newly associated lesions.
• Pathological features, proliferative index, and genetic/biochemical parameters show potential for predicting malignancy.

Conclusions:

• Genetic mutations significantly contribute to pheochromocytoma and paraganglioma development and associated syndromes.
• Pathologists play a crucial role in validating markers to predict the malignant potential of these tumors.